XXXX third to quarter Thank conference call. and our welcome you, Ping
appeal various continue proprietary Further gene expand collaborations of based our to to on we third the and and expression multiple our fronts. our broad partners the potential highlighting quarter, During strengthen platform. CX application
our Top sectors. We progress as with in continue to partner-lead Tier their many collaborations entering strong collaborations, well companies additional into research respective scientific in as make of
In within communities, and continue investors grow. several visibility investor industry addition, active and we presentations peers and remain at investment as with making and conferences, our industry awareness our to
at scientific me highlight the As look a particularly front. the we few quarter, let notable achievements first on
animal animal announced therapeutic one we of sector In with the fifth technology collaboration, to three commercial of demonstrate for diseases, our the to potential use health potentially of the health animal health sector, largest health companion and types agreement farm in and animal, recently different companies fully projects. funded considering for production expression proteins CX
signed protein company. third segment second entered company research into twice a with we expanded major to collaboration successful the them. first we're the as this may this is protein, collaboration expression have the earlier express recall agreement And a leading in they protein, collaboration has working another health health for animal animal now you This a initial year, of and Dyadic already this Since one extend on with
studies CX data seems In Schmallenberg initial initial the times and this the virus XX and collaboration, in regards started than level, of expressed were ZAPI more target to the mice animal promising. where cattle
believe as the as in validated important from collaborations impact ZAPI, results final in data that months. coming ZAPI companies. couple have expect parties we However, to We on within animal well an studies will successful animal a health other our of receive the
very manufacturing by growing in shorter animal commercialization. time is and model approach cost a less addressable a the as animal The faster health characterized reimbursement important Each large there to collaboration competitive development, care is Tampa targeted market, market. is costs, is a expensive Sector more consideration also highlight business pathway, of to regulatory and development health our biologics Health
of pocket owners animals. is most an So, expense of it for out companion
For farm volumes animals, the demand is pressure. in translates into strong, which high margin
We contributing the an market factors to is and that cost success believe gaining appear in are initial others issue. our these where be to again, So, traction. we
third the also company different tier in to with continue make In human fronts. proteins In progress types we healthcare. express August, for collaboration another at fully funded top three classes several we signed in quarter, pharmaceutical other research to
progressing very with collaboration of Our Serum Institute well. the is India
to gene our human work continue More proteins expressed begun to sequences than transferred efforts CX. At structures The glycan us. progress from VTT, like are XX in promising. has have been engineering and in glycol initial results half of scientific impark and make earnest, we the the to the
further to efforts. resources the increase we and support glycoengineering help our Additionally,
to glycoengineering first We updates the of half and XXXX. expect results additional provide in
Alphazyme fermentation regard In the sign to the to off and to the signed them complete off on for we're collaboration, the technology, technology transfer. portion waiting remaining
some summarize us Let takeaways. key
globally over animal with more healthcare society scientific with collaborations for year clearly creating top pharma we health, of a proof-of-concept into for And XX human cost over effective commercially and First, the seven efficient both a companies. half, solutions entered is just resonating community. our working and vision and
we vectors, And research to metabolite. funded express a this can Evaluating, and CX for research viral A, B, initiated AAV secondary We're additional make funded in projects. projects progress both where internally two continuing year. internally
on pegol, the to Cimzia, BioBetters drug the work used psoriasis, first biologic €X.X UCB's and biosimilar be disease, Crohn's rheumatoid both to potential BioBetters, would for our which continuing biosimilar, which is projects, fragment billion We're arthritis. antibody a treat PEGylated of Certolizumab
cancer two, to currently a billion in been over reported $X costly to the next potential to year like BioBetters Bristol-Myers Nivolumab, projected sales, has over and is which And or $X have a related monoclonal which billion. be Squibb drug Opdivo, reach antibody biosimilar,
of development sector both to faster cost large approach collaborators, a our targeted expensive less opportunistic. Our case time are growing by to animal is and building health characterized shorter on a In and regulatory pathway, we market value the that focused and is commercialization.
biotech they sign-off of smaller human on as portfolio in will started BDI, These our technology the after In received CX VLPbio which creating companies include Alphazyme, we transfer. addition, tech currency. and be currently using Novovet, have equity stakes attractive
Health In for October, on of as agreement based immunotherapeutics technology. endorsement activities. animals discover and see Bayer jointly an to VLPs additional collaboration signed VLP VLPs this global a We and Animal develop
We manage our securities and continue cash to investment grade carefully.
remains we Our approximately $XX.X including cash financial XXXX securities, September position anticipate Currently, end we that we'll as of projected. million solid, XXth cash, more with grade than previously with investment accrued in interest.
we operations no now extraordinary million be and $XX the the between will burn number between that Currently, and end the expect of You with for anticipated gave of XXXX. events year year, end assuming we may than remember $X that million. cash from $X we previously guidance the the at less the that million
inflows, million million our investment exercise cash is million. income cash AMT be cash other approximately to which $X.X of After the in our expect to to we with approximately as tax interest and grade considering and million $XX $X.X to expected year refund, options, $XX end net year such means the securities, for the burn
We are free. also debt
With that, for I Ping will turn the call review. her to financial
